Monoamine oxidase type B (MAO-B) inhibitors represent one of the most established and commercially successful therapeutic classes in Parkinson's disease (PD) treatment. Three FDA-approved drugs—selegiline, rasagiline, and safinamide—generate combined annual revenues exceeding $500 million globally. The class offers neuroprotective potential beyond symptomatic relief, making it attractive for disease-modifying therapy development. This investment landscape analyzes the current market, pipeline, research gaps, and investment opportunities in the MAO-B inhibitor space.
The global MAO-B inhibitor market is valued at approximately $600-700 million annually, with steady growth driven by: (1) increasing PD prevalence, (2) earlier treatment initiation, and (3) combination therapy adoption. [@parkinsons]
Market Drivers
Aging population: Global PD cases projected to reach 12 million by 2040
Disease-modifying potential: MAO-B inhibitors shown to reduce oxidative stress and may slow disease progression
Combination therapy: Growing use with levodopa and dopamine agonists
Generic competition: Patent expirations creating value opportunities for novel formulations
Pipeline Analysis
Clinical Trials
As of 2026, ClinicalTrials.gov lists approximately 45 active or completed trials involving MAO-B inhibitors: [@teva]
Phase 3: 8 trials (mostly combination studies with levodopa)
NIH funding for MAO-B research has remained relatively stable at $4-5 million annually, with increasing focus on: (1) biomarkers for neuroprotection, (2) combination therapies, and (3) novel drug delivery systems.
Insufficient research on MAO-B in non-PD neurodegenerative conditions
Underfunded comparative effectiveness studies
Lack of biomarkers for treatment response prediction
Competitive Landscape
Key Players
Teva Pharmaceuticals: Dominant player with Azilect (rasagiline), pursuing next-generation formulations
Zambon/Supernus: Safinamide (Xadago) with patent protection through 2028
Somerset Pharmaceuticals: Generic selegiline and transdermal formulations
Mitsubishi Tanabe: Novel MAO-B inhibitors in development
Generic Impact
Selegiline: Generic since 2014
Rasagiline: Generic since 2022 (US)
Safinamide: Patent expiry approaching (2028)
Generic competition has significantly impacted revenue but created opportunities for: (1) novel formulations, (2) combination products, and (3) geographic expansion.
Research Gaps
Unmet Needs
Disease modification: No MAO-B inhibitor has demonstrated definitive disease-modifying effects in large trials
Biomarkers: Lack of validated biomarkers for neuroprotection
Combination therapy optimization: Optimal sequencing and dosing unclear
Non-motor symptoms: Limited data on cognitive, autonomic benefits
Early intervention: No approved use in prodromal PD
Neuroprotection trials: Cost and duration barriers
Unknown, NIH RePORTER MAO-B Research Funding Data (n.d.)
Unknown, Parkinson's Disease Foundation Epidemiology Statistics (n.d.)
Unknown, Teva Azilect Product Information (n.d.)
Pathway Diagram
The following diagram shows the key molecular relationships involving MAO-B Inhibitors for Parkinson's Disease — Investment Landscape Analysis discovered through SciDEX knowledge graph analysis: